Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.
A 59-year-old female was admitted to Tsukuba University Hospital and diagnosed as IgA-lambda multiple myeloma (stage IIIA). No cardiovascular disorder with the exception of minor ischemic changes in ECG was revealed before treatment. Recombinant human alpha-interferon (IFN) at a dose of 3 million units combined with melphalan and prednisolone was administrated. Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF). Treatment with diuretics and catecholamine products showed almost complete recovery from CHF in 3 weeks. An adverse reaction to IFN was strongly suspected as the cause of CHF.
Kobayashi
T
T
Division of Hematology, University of Tsukuba, Japan.
Sato
Y
Y
Hasegawa
Y
Y
Nagasawa
T
T
Yoda
Y
Y
Abe
T
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D007370:Interferon Type I / Q000009:adverse effects* / Q000627:therapeutic use; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D010956:Plasmapheresis; D011239:Prednisolone / Q000008:administration & dosage; D011994:Recombinant Proteins; D014751:Vindesine / Q000008:administration & dosage
D002316:Cardiotonic Agents; D004232:Diuretics; D007155:Immunologic Factors; D007370:Interferon Type I; D011994:Recombinant Proteins; D003520:Cyclophosphamide; D011239:Prednisolone; D008558:Melphalan; D014751:Vindesine